Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other solid neoplasm 1Myeloid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Uveal Melanoma 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Immunoblastic Lymphadenopathy 1Graft vs Host Disease 1

Interventions

Peripheral Blood Stem Cell Transplantation 42fludarabine phosphate 37Cyclophosphamide 36Mycophenolic Acid 28Whole-Body Irradiation 26Cyclosporine 25Busulfan 25Tacrolimus 22Antilymphocyte Serum 21Methotrexate 16Filgrastim 16Etoposide 15Methylprednisolone 13Melphalan 13Radiotherapy 12Flow Cytometry 11Psychiatric Rehabilitation 10Therapeutics 9Rituximab 9Polymerase Chain Reaction 8Bortezomib 8Gemcitabine 7Cord Blood Stem Cell Transplantation 7sargramostim 6Vorinostat 6Sirolimus 6tanespimycin 5Transplantation 5Thiotepa 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × ruxolitinib × Dermatologic × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡